



HEALTH HOLDING

HAFER ALBATIN HEALTH  
CLUSTER

MATERNITY AND  
CHILDREN HOSPITAL

|                          |   |                         |               |
|--------------------------|---|-------------------------|---------------|
| <b>Department:</b>       | Laboratory and Blood Bank ( Chemistry ) |                         |               |
| <b>Document:</b>         | Internal Policy and Procedure           |                         |               |
| <b>Title:</b>            | Analysis of Chloride Level              |                         |               |
| <b>Applies To:</b>       | All Laboratory Staff                    |                         |               |
| <b>Preparation Date:</b> | January 06, 2025                        | <b>Index No:</b>        | LB-IPP-156    |
| <b>Approval Date:</b>    | January 20, 2025                        | <b>Version :</b>        | 2             |
| <b>Effective Date:</b>   | February 20, 2025                       | <b>Replacement No.:</b> | LB-IPP-156(1) |
| <b>Review Date:</b>      | February 20, 2028                       | <b>No. of Pages:</b>    | 04            |

## 1. PURPOSE:

- 1.1 The purpose of this policy & procedure is to provide all information related to the analysis of Analysis of Chloride level in blood (serum/plasma) & urine on DimensionEXL200 ,Synchron DXC700 and Atelica CI machines.

## 2. DEFINITONS:

- 2.1 Chloride is an electrolyte. It is a negatively charged ion that works with other electrolytes, such as potassium, sodium, and bicarbonate, to help regulate the amount of fluid in the body and maintain the acid-base balance. This test measures the level of chloride in the blood and/or urine.

## 3. POLICY:

- 3.1 Chloride is an electrolyte that helps balance the amount of fluid inside and outside of cells. It also helps maintain blood volume, blood pressure, and the pH of body fluids.
- 3.2 The normal range for chloride is between 98 and 107 milliequivalents per liter (mmol/L), Chloride levels above the normal range cause a condition known as hyperchloremia. Hyperchloremia happens when the volume of chloride ions rises, which might be due to a number of factors as Severe dehydration, Diarrhoea and excessive urination, Metabolic acidosis, Kidney disease and Chemotherapy, Hyperchloremia is common in critically ill people.
- 3.3 Hypochloreaemia happens when the volume of chloride ions decreases. Possible causes include:Low salt intake in the diet, Metabolic alkalosis, Certain medications, such as diuretics and laxatives, Addison's Disease.

## 4. PROCEDURE:

### 4.1 Specimen:

#### 4.1.1 Type:

- 4.1.1.1 Serum, plasma or urine.

#### 4.1.2 Tube Type:

- 4.1.2.1 Gel tube, Plain tube; Li-Heparin, and urine containers.

#### 4.1.3 Amount Required:

- 4.1.3.1 2.0 to 3.0 ml blood,24h urine sample

#### 4.1.4 Delivery Arrangements:

- 4.1.4.1 Sample to be delivered to the lab as soon as possible. If the sample is serum should be ensuring complete clot formation before centrifugation. Some specimens, especially those from patients receiving anticoagulant or thrombolytic therapy, may exhibit increased clotting time. If the specimen is centrifuged before a complete clot forms, the presence of fibrin may cause erroneous results.

#### 4.1.5 Temperature Restrictions:

- 4.1.5.1 At room temperature.

#### 4.1.6 Unacceptable Specimen:



- 4.1.6.1 See sample rejection criteria policy.
- 4.1.7 Specimen Retention:
  - 4.1.7.1 Period of retention: up to one week after separation of the sample.
  - 4.1.7.2 Storage condition: store at 2-8 °C
- 4.1.8 Safety Precaution:
  - 4.1.8.1 Treat all samples material as infectious and handled in accordance with the OHSA standard on blood borne pathogens.
- 4.2 **Principle:** Indirect potentiometric technique
  - 4.2.1 There are five electrodes used to measure electrolytes on the Dimension system. Three of these electrodes are incorporated into the QuikLYTE® integrated multisensor and are ion selective for sodium, potassium and chloride. A reference electrode is also incorporated in the multisensor. After a diluted sample is positioned in the sensor Na<sup>+</sup>, K<sup>+</sup> and Cl<sup>-</sup> ions establish an equilibrium with the electrode surface. A potential is generated proportional to the logarithm of the analyte activity in the sample. The electrical potential generated on a standard solution, and the concentration of the desired ions is calculated by use of the Nernst equation.
- 4.3 **Method:**
  - 4.3.1 See policy of loading sample on machine (Ref: Operative Manuals' of DimensionEXL200 ,Synchron DXC700 and Atelica CI
- 4.4 **Calculation:**
  - 4.4.1 Instrument system automatically calculates the Analytic activity and gives results in the form of print out.
- 4.5 **Format:**
  - 4.5.1 Numeric
- 4.6 **References range:**
  - 4.6.1 Serum/plasma: 98-107 (mmol/L)
  - 4.6.2 Urine: 110-250 (mmol/24hr)
- 4.7 **Dilution Information:**
  - 4.7.1 Specimens with values exceeding the linearity range are flagged and diluted with the automatic dilution.
- 4.8 **Test Limitation:**
  - 4.8.1 Recognizing:
    - 4.8.1.1 Haemolysed sample (HB>500 mg/dl)
    - 4.8.1.2 Lipemia: because of absorbance flagging > 1000 mg/dl
    - 4.8.1.3 Icterus: bilirubin > 94 mg/dl
  - 4.8.2 Avoiding Error:
    - 4.8.2.1 Following acceptance criteria of the sample
    - 4.8.2.2 By following the maintenance protocol. Daily, weekly, month
    - 4.8.2.3 Run control before starting the tests
  - 4.8.3 Error Correction:
    - 4.8.3.1 Look for a fibrin clot or air bubbles
    - 4.8.3.2 Repeat the sample from the original tube
    - 4.8.3.3 Ask for another sample
- 4.9 **Specific Performance Characteristics:**
  - 4.9.1 Assay range:
    - 4.9.1.1 Serum/plasma: 50 - 200 mmol/L
    - 4.9.1.2 Urine: 10 - 330 mmol/L

## 5. MATERIALS AND EQUIPMENT:

- 5.1 **Reagent:**
  - 5.1.1 QuikLYTE® Standard A
  - 5.1.2 QuikLYTE® Standard B
  - 5.1.3 QuikLYTE® Flush Solution
  - 5.1.4 QuikLYTE® Sample Diluent
  - 5.1.5 QuikLYTE® Dilution Check



#### 5.1.6 Salt Bridge Solution

### 5.2 Calibration:

5.2.1 Refer to insert sheet of QuikLYTE® integrated multisensor.

### 5.3 Quality control:

5.3.1 Normal and pathological control. One time in 24 hours (once per day).

5.3.2 If more frequent control monitoring is required, follow the established quality control procedures your laboratory.

5.3.3 If quality control results do not fall within an acceptable range defined by your laboratory, may be affected and corrective action should be taken.

5.3.4 Quality Control retention:

5.3.3.1 Unopened control vial is stable up to expiry date printed on the label when stored at cold room.

5.3.3.2 Opened control vial is stable for: After reconstituting and tightly capped at 2 — 8 °C All analytes will be stable for 7 days .

5.3.5 QC Procedure: Verify that the correct QC values have been entered into the QC file. For details refer to Operator Guide of DimensionEXL200.

5.3.5.1 Allow QC to come to room temperature.

5.3.5.2 Gently remove the stopper to avoid loss of the lyophilized pellet and add exactly 5.0 ml distilled or de-ionized water.

5.3.5.3 Leave to stand for 20 minutes.

5.3.5.4 Mix bottle several times by inversion to allow homogeneity.

5.3.5.5 Gently invert just prior to use. Avoid foaming.

5.3.5.6 Open bottle, place a minimum of 1000 ul of each level in separate sample cup, and place on the assigned positions.

5.3.5.7 Cap bottle tightly and store at 2-8°C. Immediately after use.

5.3.5.8 Perform QC as indicated in Operator Guide of DimensionEXL200 ,Synchron DXC700 and Atelica CI machines.

5.3.6 QC Expected Values:

5.3.6.1 Refer to the Bio-Rad Lyphocheck assayed chemistry controls value sheet for Dimension.

## 6. RESPONSIBILITIES:

6.1 Chemistry shift on charge is responsible for, running calibration and control and samples of chloride.

6.2 Chemistry staff are responsible for running Na samples all over the day

## 7. APPENDICES:







7.1 N/A

## 8. REFERENCES:

8.1 Tietz Text Book of clinical chemistry and molecular diagnostics 4th Edition,2006

8.2 Company Leaflets of reagents, and machine operator.

## 9. APPROVALS:

|                     | Name                          | Title                              | Signature   | Date             |
|---------------------|-------------------------------|------------------------------------|---|------------------|
| <b>Prepared by:</b> | Dr. Talal Abdelgawad          | Clinical Pathologist               |  | January 06, 2025 |
| <b>Reviewed by:</b> | Dr. Kawther M. Abdou          | Consultant & Lab. Medical Director |  | January 13, 2025 |
| <b>Reviewed by:</b> | Ms. Noora Melfi Alanizi       | Laboratory & Blood Bank Director   |  | January 13, 2025 |
| <b>Reviewed by:</b> | Mr. Abdulelah Ayed Al Mutairi | QM&PS Director                     |  | January 13, 2025 |
| <b>Reviewed by:</b> | Dr. Tamer Mohamed Naguib      | Medical Director                   |   | January 13, 2025 |
| <b>Approved by:</b> | Mr. Fahad Hazam Alshammari    | Hospital Director                  |  | January 20, 2025 |